These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 15615641)
1. Modeling tauopathy: a range of complementary approaches. Hall GF; Yao J Biochim Biophys Acta; 2005 Jan; 1739(2-3):224-39. PubMed ID: 15615641 [TBL] [Abstract][Full Text] [Related]
2. Tau Fibril Formation in Cultured Cells Compatible with a Mouse Model of Tauopathy. Matsumoto G; Matsumoto K; Kimura T; Suhara T; Higuchi M; Sahara N; Mori N Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772786 [TBL] [Abstract][Full Text] [Related]
3. A seeding based cellular assay of tauopathy. Xu Y; Martini-Stoica H; Zheng H Mol Neurodegener; 2016 Apr; 11():32. PubMed ID: 27112488 [TBL] [Abstract][Full Text] [Related]
4. Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse model. Cook C; Kang SS; Carlomagno Y; Lin WL; Yue M; Kurti A; Shinohara M; Jansen-West K; Perkerson E; Castanedes-Casey M; Rousseau L; Phillips V; Bu G; Dickson DW; Petrucelli L; Fryer JD Hum Mol Genet; 2015 Nov; 24(21):6198-212. PubMed ID: 26276810 [TBL] [Abstract][Full Text] [Related]
5. The twenty-four KDa C-terminal tau fragment increases with aging in tauopathy mice: implications of prion-like properties. Matsumoto SE; Motoi Y; Ishiguro K; Tabira T; Kametani F; Hasegawa M; Hattori N Hum Mol Genet; 2015 Nov; 24(22):6403-16. PubMed ID: 26374846 [TBL] [Abstract][Full Text] [Related]
6. Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies. Zilka N; Korenova M; Novak M Acta Neuropathol; 2009 Jul; 118(1):71-86. PubMed ID: 19238406 [TBL] [Abstract][Full Text] [Related]
7. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011 [TBL] [Abstract][Full Text] [Related]
8. Tau phosphorylation and aggregation as a therapeutic target in tauopathies. Badiola N; Suárez-Calvet M; Lleó A CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789 [TBL] [Abstract][Full Text] [Related]
9. Longitudinal assessment of a transgenic animal model of tauopathy by FDG-PET imaging. de Cristóbal J; García-García L; Delgado M; Pérez M; Pozo MA; Medina M J Alzheimers Dis; 2014; 40 Suppl 1():S79-89. PubMed ID: 24577468 [TBL] [Abstract][Full Text] [Related]
10. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Brandt R; Hundelt M; Shahani N Biochim Biophys Acta; 2005 Jan; 1739(2-3):331-54. PubMed ID: 15615650 [TBL] [Abstract][Full Text] [Related]
11. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Wittmann CW; Wszolek MF; Shulman JM; Salvaterra PM; Lewis J; Hutton M; Feany MB Science; 2001 Jul; 293(5530):711-4. PubMed ID: 11408621 [TBL] [Abstract][Full Text] [Related]
12. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Shiryaev N; Jouroukhin Y; Giladi E; Polyzoidou E; Grigoriadis NC; Rosenmann H; Gozes I Neurobiol Dis; 2009 May; 34(2):381-8. PubMed ID: 19264130 [TBL] [Abstract][Full Text] [Related]
13. Tau oligomers as potential targets for early diagnosis of tauopathy. Sahara N; Ren Y; Ward S; Binder LI; Suhara T; Higuchi M J Alzheimers Dis; 2014; 40 Suppl 1():S91-6. PubMed ID: 24595194 [TBL] [Abstract][Full Text] [Related]
14. Targeting tauopathy with engineered tau-degrading intrabodies. Gallardo G; Wong CH; Ricardez SM; Mann CN; Lin KH; Leyns CEG; Jiang H; Holtzman DM Mol Neurodegener; 2019 Oct; 14(1):38. PubMed ID: 31640765 [TBL] [Abstract][Full Text] [Related]
15. Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load. Koson P; Zilka N; Kovac A; Kovacech B; Korenova M; Filipcik P; Novak M Eur J Neurosci; 2008 Jul; 28(2):239-46. PubMed ID: 18702695 [TBL] [Abstract][Full Text] [Related]
16. Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates. Vega IE; Cui L; Propst JA; Hutton ML; Lee G; Yen SH Brain Res Mol Brain Res; 2005 Aug; 138(2):135-44. PubMed ID: 15913839 [TBL] [Abstract][Full Text] [Related]
17. A mouse model to study tau pathology related with tau phosphorylation and assembly. Engel T; Lucas JJ; Hernández F; Avila J J Neurol Sci; 2007 Jun; 257(1-2):250-4. PubMed ID: 17362999 [TBL] [Abstract][Full Text] [Related]
18. Differential regional distribution of phosphorylated tau and synapse loss in the nucleus accumbens in tauopathy model mice. Kambe T; Motoi Y; Inoue R; Kojima N; Tada N; Kimura T; Sahara N; Yamashita S; Mizoroki T; Takashima A; Shimada K; Ishiguro K; Mizuma H; Onoe H; Mizuno Y; Hattori N Neurobiol Dis; 2011 Jun; 42(3):404-14. PubMed ID: 21324362 [TBL] [Abstract][Full Text] [Related]
19. Raphé tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease. Menuet C; Borghgraef P; Matarazzo V; Gielis L; Lajard AM; Voituron N; Gestreau C; Dutschmann M; Van Leuven F; Hilaire G Respir Physiol Neurobiol; 2011 Sep; 178(2):290-303. PubMed ID: 21763469 [TBL] [Abstract][Full Text] [Related]
20. Tau pathology in Alzheimer disease and other tauopathies. Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]